ELISA/assay

ELISA Kit for Transforming Growth Factor Beta 2 (TGFb2)

MBS2020779

48-Strip-Wells

540 USD

ELISA Kit

ELISA Kit for Transforming Growth Factor Beta 2 (TGFb2)

Transforming Growth Factor Beta 2 (TGFb2)

transforming growth factor beta 2; Transforming growth factor beta-2; transforming growth factor beta-2; BSC-1 cell growth inhibitor; G-TSF; cetermin; glioblastoma-derived T-cell suppressor factor; polyergin; prepro-transforming growth factor beta-2; transforming growth factor, beta 2; BSC-1 cell growth inhibitor; Cetermin; Glioblastoma-derived T-cell suppressor factor; G-TSF; PolyerginLatency-associated peptide; LAP

TGFb2

TGFB2; TGFB2; LDS4; TGF-beta2; TGF-beta-2; G-TSF; LAP

TGFB2_HUMAN

Mouse

413

This assay has high sensitivity and excellent specificity for detection of TGFb2. No significant cross-reactivity or interference between TGFb2 and analogues was observed.

For unopened kit, all the reagents should be kept according to the label on each vial. The Standard, Detection Reagent A, Detection Reagent B and the 96-well strip plate should be stored at -20 degree C while others should be at 4 degree C.

Samples: Mouse serum, plasma, tissue homogenates, cell culture supernates and other biological fluids. Detection Range: 31.2-2,000pg/mL. Sensitivity: The minimum detectable dose of TGFb2 is typically less than 13.4pg/mL. The sensitivity of this assay, or Lower Limit of Detection (LLD) was defined as the lowest protein concentration that could be differentiated from zero. It was determined by adding two standard deviations to the mean optical density value of twenty zero standard replicates and calculating the corresponding concentration.

Intra-assay Precision: Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level TGFb2 were tested 20 times on one plate, respectively. Intra-Assay: CV<10%. Inter-assay Precision: Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level TGFb2 were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100. Inter-Assay: CV<12%. Intended Uses: The kit is a sandwich enzyme immunoassay for in vitro quantitative measurement of TGFb2 in mouse serum, plasma, tissue homogenates, cell culture supernates and other biological fluids.

Principle of the assay: The microtiter plate provided in this kit has been pre-coated with an antibody specific to TGFb2. Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to TGFb2. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain TGFb2, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm +/- 10nm. The concentration of TGFb2 in the samples is then determined by comparing the O.D. of the samples to the standard curve.

557563

AAA50405.1

P61812

50,573 Da

ATF-2 Transcription Factor Network Pathway (138006); Amoebiasis Pathway (167324); Amoebiasis Pathway (167191); Cell Cycle Pathway (83054); Cell Cycle Pathway (463); Chagas Disease (American Trypanosomiasis) Pathway (147809); Chagas Disease (American Trypanosomiasis) Pathway (147795); Chronic Myeloid Leukemia Pathway (83116); Chronic Myeloid Leukemia Pathway (528); Colorectal Cancer Pathway (83106)

This gene encodes a member of the transforming growth factor beta (TGFB) family of cytokines, which are multifunctional peptides that regulate proliferation, differentiation, adhesion, migration, and other functions in many cell types by transducing their signal through combinations of transmembrane type I and type II receptors (TGFBR1 and TGFBR2) and their downstream effectors, the SMAD proteins. Disruption of the TGFB/SMAD pathway has been implicated in a variety of human cancers. The encoded protein is secreted and has suppressive effects of interleukin-2 dependent T-cell growth. Translocation t(1;7)(q41;p21) between this gene and HDAC9 is associated with Peters' anomaly, a congenital defect of the anterior chamber of the eye. The knockout mice lacking this gene show perinatal mortality and a wide range of developmental, including cardiac, defects. Alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Sep 2010]

TGFB2: TGF-beta 2 has suppressive effects on interleukin-2 dependent T-cell growth. Homodimer; disulfide-linked. Heterodimers with TGFB1 and with TGFB3 have been found in bone. Interacts with the serine proteases, HTRA1 and HTRA3. Interacts with ASPN. Belongs to the TGF-beta family. 2 isoforms of the human protein are produced by alternative splicing. Protein type: Cell development/differentiation; Secreted, signal peptide; Motility/polarity/chemotaxis; Secreted. Chromosomal Location of Human Ortholog: 1q41. Cellular Component: extracellular matrix; extracellular space; cell soma; axon; extracellular region; endosome. Molecular Function: protein binding; protein homodimerization activity; growth factor activity; protein heterodimerization activity; beta-amyloid binding; punt binding; cytokine activity; transforming growth factor beta receptor binding; receptor binding; receptor signaling protein serine/threonine kinase activity. Biological Process: heart morphogenesis; extracellular matrix organization and biogenesis; collagen fibril organization; catagen; heart development; dopamine biosynthetic process; SMAD protein nuclear translocation; protein amino acid phosphorylation; hair follicle development; cell-cell signaling; transforming growth factor beta receptor signaling pathway; somatic stem cell division; cell growth; cell cycle arrest; embryonic gut development; cartilage condensation; response to drug; platelet activation; neutrophil chemotaxis; negative regulation of immune response; neuron fate commitment; positive regulation of cell cycle; positive regulation of catagen; positive regulation of cell growth; positive regulation of phosphoinositide 3-kinase cascade; cardioblast differentiation; positive regulation of protein secretion; positive regulation of cell division; activation of protein kinase activity; neuron development; response to progesterone stimulus; positive regulation of heart contraction; cell death; axon guidance; positive regulation of immune response; wound healing; cell morphogenesis; cardiac muscle cell proliferation; positive regulation of stress-activated MAPK cascade; odontogenesis; negative regulation of cell proliferation; platelet degranulation; positive regulation of neuron apoptosis; salivary gland morphogenesis; positive regulation of cell proliferation; response to wounding; hemopoiesis; angiogenesis; positive regulation of integrin biosynthetic process; negative regulation of epithelial cell proliferation; uterine wall breakdown; intercellular junction assembly and maintenance; cell migration; regulation of transforming growth factor-beta2 production; hair follicle morphogenesis; positive regulation of cell adhesion mediated by integrin; glial cell migration; positive regulation of ossification; cell proliferation; embryonic development; eye development; generation of neurons; positive regulation of cardioblast differentiation; response to hypoxia; epithelial to mesenchymal transition; blood vessel remodeling; negative regulation of cell growth; blood coagulation. Disease: Loeys-dietz Syndrome 4

48-Strip-Wells

540 USD

96-Strip-Wells

730

5x96-Strip-Wells

2760

10x96-Strip-Wells

4985